Pre-made Anetumab benchmark antibody ( Whole mAb ADC, anti-MSLN therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-025
Anti-MSLN therapeutic antibody (Pre-made Anetumab biosimilar,Whole mAb ADC) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Anetumab ravtansine, here referred to as BAY 94-9343, a novel ADC consisting of a human anti-mesothelin antibody conjugated to the maytansinoid tubulin inhibitor DM4 via a disulfide-containing linker.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-MSLN therapeutic antibody (Pre-made Anetumab biosimilar,Whole mAb ADC)|
|Format||Whole mAb ADC|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Bayer HealthCare;ImmunoGen;MorphoSys;National Cancer Institute (USA)|
|Conditions Active||Lung cancer;Mesothelioma;Ovarian cancer;Pancreatic cancer;Solid tumours;Non-small cell lung cancer;Malignant thymoma|
|Conditions Discontinued||Fallopian tube cancer;Peritoneal cancer|
|Development Tech||MorphoSys HuCAL Phage Display|